DEFEROXAMINE MESYLATE

Post-LOE

Hikma

ANDAINJECTIONINJECTABLE

Approved

May 2007

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

DEFEROXAMINE MESYLATE by Hikma is reactions. Approved for primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder), transfusional iron overload in patients with chronic anemia. First approved in 2007.

Drug data last refreshed 23h ago

$0.0BPart D

Mechanism of Action

reactions. It readily chelates iron from ferritin and hemosiderin but not readily from transferrin; it does not combine with the iron from cytochromes and hemoglobin. Deferoxamine mesylate does not cause any demonstrable increase in the excretion of electrolytes or trace metals. Theoretically, 100…

Indications (2)

primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder)transfusional iron overload in patients with chronic anemia

Worked on DEFEROXAMINE MESYLATE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.